Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
ABSTRACT: #102
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including #102synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at Â鶹ӳ» MD?Anderson Cancer Center.
Among 38...
Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
ABSTRACT: #109
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety...
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate...
Novel targeted drug induced positive response for patients with von Hippel-Lindau disease¨Cassociated kidney cancer
ABSTRACT: #5003
In an international trial led by researchers at Â鶹ӳ» MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)¨Cassociated renal cell carcinoma (RCC).
The results of the Phase II trial were shared today in an oral presentation...
Combination therapy well-tolerated and highly effective for patients with IDH1-mutated acute myeloid leukemia (AML)
ABSTRACT: #7500
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective...
MD Anderson and Innovent Biologics announce a strategic collaboration to develop anti-PD-1 therapy TYVYT? (sintilimab injection) in rare cancers
Â鶹ӳ» MD Anderson Cancer Center and Innovent Biologics, Inc. today announced a strategic collaboration agreement to co-develop...